Humalog ® (insulin lispro)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: (England, Scotland, Wales) or (Northern Ireland).

HUMALOG® Insulin: Use in Patients With COVID-19 (Coronavirus disease 2019)

The use of Humalog insulin in patients with COVID-19 has not been studied.

Use of HUMALOG Insulin in Patient With COVID-19

COVID-19 is an infectious respiratory disease caused by SARS-CoV-2, previously referred to as "2019 novel coronavirus."1

Lilly has not studied the use of Humalog Insulin in patients with COVID-19 nor in patients at risk of contracting COVID-19.

The Humalog insulin label doesn't state any specific recommendations. However, it does state that insulin requirements may be increased during illness or emotional disturbances.2

Insulin requirements may be increased by substances with hyperglycaemic activity, such as corticosteroids. Insulin requirements may be reduced in the presence of substances with hypoglycaemic activity, such as salicylates (for example, acetylsalicylic acid).2

Clinicians should use their clinical judgment in determining the most appropriate approach in treating a patient with Humalog insulin who has confirmed or suspected COVID-19.

Infectious Disease Resources for COVID-19

For current information on COVID-19, please refer to


1. Naming the coronavirus disease (COVID-19) and the virus that causes it. World Health Organization. Accessed March 17, 2020.

2. Humalog [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

3. Coronavirus disease (COVID-19) outbreak. European web page of the World Health Organization. Accessed March 20, 2020.

4. International Diabetes Federation Europe. COVID-19 outbreak: guidance for people with diabetes. Accessed March 18, 2020

5. COVID-19. European Centre for Disease Prevention and Control. Accessed March 20, 2020.


COVID-19 = coronavirus disease 2019

ECDC = European Centre for Disease Prevention and Control

EU WHO = World Health Organization (European regional office)

IDF = International Diabetes Federation

Lilly = Eli Lilly and Company

SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2

Date of Last Review: 17 March 2020

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request